VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies
Hiba Laraki, Ibtissam Rezouki, Khalil Choukri, Abdallah Badou · 2025
Read VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies by Hiba Laraki, Ibtissam Rezouki, Khalil Choukri, Abdallah Badou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780148.txt.
Description
Hiba Laraki and three co-authors review VISTA, an immune brake that cancer immunotherapy has barely touched, in a 2025 paper. Drugs releasing the famous PD-1 brake fail many patients, so the hunt is on for the next checkpoint.
VISTA belongs to the B7 family and sits on blood-forming cells. It damps T cell activity and blunts anti-tumor responses. The review maps where it appears across cancers and what roles it plays there. Candidate partner molecules get a hearing, with the tumor's neighborhood in view. Clinical trials targeting VISTA are summarized at the end. The authors cast it as a promising, still-early lever: strong biology, few answers in patients so far.
Catalog record
| CREATOR | Hiba Laraki, Ibtissam Rezouki, Khalil Choukri, Abdallah Badou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |